Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China

Condividi: 26 gennaio 2021 BOSTON and BEIJING, Jan. 26, 2021 /PRNewswire/ — Eucure Biopharma, a subsidiary of Biocytogen, announced the first patient enrollment for a Phase I clinical trial in China to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of…

Leggi Biocytogen Subsidiary Eucure Biopharma Reports First Patient Enrolled in anti-CTLA4 Phase I Trial in China